The current financial score of NewGenIvf Group Ltd is 5.94. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.42M, representing a year-over-year increase of 11.85%, while its net profit experienced a year-over-year increase of 6984.91%.
The current valuation score of NewGenIvf Group Ltd is 9.96. Its current P/E ratio is 0.00, which is 320602666.67% below the recent high of 961.81 and 82077166.67% above the recent low of -246.23.
No earnings forecast score is currently available for NewGenIvf Group Ltd. The Healthcare Providers & Services industry's average is 7.68. The average price target is 127.08, with a high of 127.08 and a low of 127.08.
The current price momentum score of NewGenIvf Group Ltd is 6.56. Currently, the stock price is trading between the resistance level at 1.45 and the support level at 0.44, making it suitable for range-bound swing trading.
The current institutional shareholding score of NewGenIvf Group Ltd is 3.00. The latest institutional shareholding proportion is 0.44%, representing a quarter-over-quarter increase of 182.33%.
The current risk assessment score of NewGenIvf Group Ltd is 1.32. The company's beta value is -0.04. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.